Table 3.

Overall survival according to various baseline factors

Variable	OS (95% CI)	Univariate analyses	Multivariate analysis
		p	HR (95% CI)	P
Total	42 (24-60)
Age
≤ 65 y	42 (29-60)	0.883
> 65 y	33 (N/A)
Ki-67 index
≤ 2%	53 (N/A)	0.082
> 2%	33 (11-55)
Hepatic tumor burden
≤ 50%	NR	0.009	2.3 (0.7-8.1)	0.183
> 50%	27 (9-45)
Tracer uptake
≤ grade 2	33 (17-49)	0.569
> grade 2	47 (34-60)
Progression at baseline*
Yes	NR	0.570
No	42 (26-58)
Bone metastases
Yes	33 (27-39)	0.710
No	53 (16-90)
Functionality
Non-functional	NR	0.306
Functional	33 (14-52)
CgA
≤ 600 ng/ml	NR	0.006	10.4 (1.3-72.8)	0.026
> 600 ng/ml	33 (23-43)
NSE
≤ 15 ng/ml	47 (34-60)	0.266
> 15 ng/ml	33 (11-55)
Histology
Typical	42 (24-60)	0.323
Atypical	35 (N/A)

^*Documented pretreatment morphologic tumor progression within 12 months before initiation of PRRT;

NR, not reached.